Aridis Pharmaceuticals Announces Proposed Public Offering of Common Stock

LOS GATOS, Calif., Sept. 26, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. ( Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it intends to offer its common stock in a public offering. The Company intends to use the net proceeds from this offering for clinical development of our product candidates, working capital and other general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.